We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) and clinical-stage biopharma company Mersana Therapeutics have forged a global collaboration, giving GSK the exclusive option to codevelop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056 targeting HER2. Read More
The company initially plans to offer the robotic system for use in knee replacement surgeries but is also planning to develop other orthopedic applications in the near future. Read More
Establishing operational limits is a key issue to consider. These are the limits that are obtained during the operational qualification (OQ) testing over the expected operating range. Read More